monitor WBC counts in patients receiving palbociclib and ribociclib, but those who develop neutropenia “generally don't feel the effects” and febrile neutropenia is uncommon, he indicated. “As we move forward,” he added, clinicians can expect “the coming
Search Results
Presenter: Alexander E. Perl
reduction from 300 to 200 mg. Febrile neutropenia is managed with antibiotics. There were no treatment-related deaths in the QUAZAR study. 6 The NCCN Guidelines do not have data on the use of FLT3 inhibitors posttransplant. Two randomized trials support
Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk
practices, Shayne et al 30 identified significant predictors of chemotherapy dose reduction, including BSA >2 m 2 , age ≥65 years, febrile neutropenia, and comorbidities (particularly renal disease). In other retrospective studies, obesity has been
Jacqueline N. Poston and Pamela S. Becker
the threshold for recommended use of growth factors in the NCCN Guidelines for MGFs. These guidelines suggest the use of growth factors for regimens that are associated with a high risk of febrile neutropenia (>20%) or an with intermediate risk (10
William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar
®. P <.001), PFS (not reached in the idelalisib group vs 5.5 months for placebo), and OS at 12 months (92% vs 80%; P =.02) compared with rituximab plus placebo. Grade 3 or 4 AEs (pneumonia, pyrexia, and febrile neutropenia) were reported in 40% of
Dawn Goetz
seen grade 3 or 4 adverse effects are neutropenia, febrile neutropenia, anemia, leukopenia, diarrhea, fatigue, and asthenia. The approximate neutrophil nadir is 12 days, and cabazitaxel carries a black box warning against giving the drug to patients
enrolled at dose level 1 (100 mg, qdx3, weekly), and 2 developed dose-limiting toxicities (DLTs). These DLTs included deep venous thrombosis/pulmonary embolism and grade IV febrile neutropenia in patient 1, and grade III febrile neutropenia and Clostridium
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Oxana V. Makarova-Rusher, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Mary A. Dwyer, and Deborah A. Freedman-Cass
risk. 61 PLWH may be more susceptible to infectious complications after chemotherapy than their uninfected counterparts, 62 and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 63 Furthermore, data show that certain
neutropenia (grade 3: 69%; grade 4: 29%), febrile neutropenia (8%), thrombocytopenia (37%), and anemia (25%). Seven patients experienced treatment-related serious AEs, with 1 grade 5 event. Of the evaluable patients, 80% and 7% achieved clinical complete and
Erin Reid, Gita Suneja, Richard F. Ambinder, Kevin Ard, Robert Baiocchi, Stefan K. Barta, Evie Carchman, Adam Cohen, Oxana V. Crysler, Neel Gupta, Chelsea Gustafson, Allison Hall, Kimberly L. Johung, Ann Klopp, Ann S. LaCasce, Chi Lin, Amitkumar Mehta, Manoj P. Menon, David Morgan, Nitya Nathwani, Ariela Noy, Lee Ratner, Stacey Rizza, Michelle A. Rudek, Julian Sanchez, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J. Wang, Sai Yendamuri, Mary A. Dwyer, CGC, and Deborah A. Freedman-Cass
uninfected counterparts to infectious complications after chemotherapy, and low CD4+ T-cell counts appear to increase the risk of febrile neutropenia. 47 Furthermore, data show that certain chemotherapy regimens can cause a sustained drop in CD4+ T
